Overview

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate